Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
We previously developed a method for determining MYCN gene amplification status using cell-free DNA fragments released from cancer cells into the blood of patients with neuroblastoma (NB). Here, we analyzed the relationship between MYCN amplification (MNA) status and neuroblastoma prognosis. We scre...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4981470?pdf=render |
| _version_ | 1819058546921177088 |
|---|---|
| author | Shigeki Yagyu Tomoko Iehara Shiro Tanaka Takahiro Gotoh Akiko Misawa-Furihata Tohru Sugimoto Wendy B London Michael D Hogarty Satoshi Teramukai Akira Nakagawara Eiso Hiyama John M Maris Hajime Hosoi |
| author_facet | Shigeki Yagyu Tomoko Iehara Shiro Tanaka Takahiro Gotoh Akiko Misawa-Furihata Tohru Sugimoto Wendy B London Michael D Hogarty Satoshi Teramukai Akira Nakagawara Eiso Hiyama John M Maris Hajime Hosoi |
| author_sort | Shigeki Yagyu |
| collection | DOAJ |
| description | We previously developed a method for determining MYCN gene amplification status using cell-free DNA fragments released from cancer cells into the blood of patients with neuroblastoma (NB). Here, we analyzed the relationship between MYCN amplification (MNA) status and neuroblastoma prognosis. We screened serum samples from 151 patients with NB for MNA, using real-time quantitative PCR, and compared the results with MYCN status determined using paired tumor samples. We additionally investigated whether MNA status correlates with patient survival. When a cut-off value of 5 was used, serum-based MNA analysis was found to show good sensitivity (86%) and very high specificity (95%). The sensitivities for stage 1 and 2 might be acceptable, even though it is not as good as for stage 3 and 4 (67% for stage 1 and 2, 92% for stage 3, and 87% for stage 4). MNA status correlated with overall survival in our cohort of 82 patients, with survival data available (p < 0.01). The hazard ratio of MNA status was 4.98 in patients diagnosed at less than 18 months of age (95% confidence interval, 1.00-24.78), and 1.41 (95% confidence interval, 0.63-3.14) for those diagnosed at 18 months of age or older. Serum-based MNA analysis is rapid and non-invasive compared with tumor-based MNA analysis, and has potential to predict tumor MNA status. There is still a room to improve the sensitivity of the test for tumors of stages 1 and 2, nonetheless this assay might help to determine therapeutic strategies prior to tumor biopsy, especially for patients with a life-threatening condition, as well as for patients of less than 18 months of age whose risk-grouping and treatment allocation depends on their MNA status. |
| first_indexed | 2024-12-21T13:56:56Z |
| format | Article |
| id | doaj.art-623bd94eed5241259ab578803041b063 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T13:56:56Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-623bd94eed5241259ab578803041b0632022-12-21T19:01:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01118e016103910.1371/journal.pone.0161039Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.Shigeki YagyuTomoko IeharaShiro TanakaTakahiro GotohAkiko Misawa-FurihataTohru SugimotoWendy B LondonMichael D HogartySatoshi TeramukaiAkira NakagawaraEiso HiyamaJohn M MarisHajime HosoiWe previously developed a method for determining MYCN gene amplification status using cell-free DNA fragments released from cancer cells into the blood of patients with neuroblastoma (NB). Here, we analyzed the relationship between MYCN amplification (MNA) status and neuroblastoma prognosis. We screened serum samples from 151 patients with NB for MNA, using real-time quantitative PCR, and compared the results with MYCN status determined using paired tumor samples. We additionally investigated whether MNA status correlates with patient survival. When a cut-off value of 5 was used, serum-based MNA analysis was found to show good sensitivity (86%) and very high specificity (95%). The sensitivities for stage 1 and 2 might be acceptable, even though it is not as good as for stage 3 and 4 (67% for stage 1 and 2, 92% for stage 3, and 87% for stage 4). MNA status correlated with overall survival in our cohort of 82 patients, with survival data available (p < 0.01). The hazard ratio of MNA status was 4.98 in patients diagnosed at less than 18 months of age (95% confidence interval, 1.00-24.78), and 1.41 (95% confidence interval, 0.63-3.14) for those diagnosed at 18 months of age or older. Serum-based MNA analysis is rapid and non-invasive compared with tumor-based MNA analysis, and has potential to predict tumor MNA status. There is still a room to improve the sensitivity of the test for tumors of stages 1 and 2, nonetheless this assay might help to determine therapeutic strategies prior to tumor biopsy, especially for patients with a life-threatening condition, as well as for patients of less than 18 months of age whose risk-grouping and treatment allocation depends on their MNA status.http://europepmc.org/articles/PMC4981470?pdf=render |
| spellingShingle | Shigeki Yagyu Tomoko Iehara Shiro Tanaka Takahiro Gotoh Akiko Misawa-Furihata Tohru Sugimoto Wendy B London Michael D Hogarty Satoshi Teramukai Akira Nakagawara Eiso Hiyama John M Maris Hajime Hosoi Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. PLoS ONE |
| title | Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. |
| title_full | Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. |
| title_fullStr | Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. |
| title_full_unstemmed | Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. |
| title_short | Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. |
| title_sort | serum based quantification of mycn gene amplification in young patients with neuroblastoma potential utility as a surrogate biomarker for neuroblastoma |
| url | http://europepmc.org/articles/PMC4981470?pdf=render |
| work_keys_str_mv | AT shigekiyagyu serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT tomokoiehara serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT shirotanaka serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT takahirogotoh serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT akikomisawafurihata serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT tohrusugimoto serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT wendyblondon serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT michaeldhogarty serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT satoshiteramukai serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT akiranakagawara serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT eisohiyama serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT johnmmaris serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma AT hajimehosoi serumbasedquantificationofmycngeneamplificationinyoungpatientswithneuroblastomapotentialutilityasasurrogatebiomarkerforneuroblastoma |